Clinical Trials Logo

Fibrillary Glomerulonephritis clinical trials

View clinical trials related to Fibrillary Glomerulonephritis.

Filter by:
  • None
  • Page 1

NCT ID: NCT06295770 Not yet recruiting - Clinical trials for Fibrillary Glomerulonephritis

Obinutuzumab in Treatment of Fibrillary Glomerulonephritis

Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this research is to learn if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis (FGN).

NCT ID: NCT06065852 Recruiting - Fabry Disease Clinical Trials

National Registry of Rare Kidney Diseases

RaDaR
Start date: November 6, 2009
Phase:
Study type: Observational [Patient Registry]

The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research. The purpose of this research is to: - Develop Clinical Guidelines for specific rare kidney diseases. These are written recommendations on how to diagnose and treat a medical condition. - Audit treatments and outcomes. An audit makes checks to see if what should be done is being done and asks if it could be done better. - Further the development of future treatments. Participants will be invited to participate on clinical trials and other studies. The registry has the capacity to feedback relevant information to patients and in conjunction with Patient Knows Best (Home - Patients Know Best), allows patients to provide information themselves, including their own reported quality of life and outcome measures.

NCT ID: NCT05546047 Active, not recruiting - Clinical trials for Fibrillary Glomerulonephritis

A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients

FACT
Start date: March 14, 2019
Phase: Phase 4
Study type: Interventional

A Multicenter, Comparative Safety and Efficacy Study of Acthar gel alone or in combination with oral Tacrolimus to reduce urinary proteinuria in patients with idiopathic DNAJB9 Positive Fibrillary glomerulopathy.

NCT ID: NCT02197767 Completed - Clinical trials for Fibrillary Glomerulonephritis

Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis

Start date: November 2014
Phase: Phase 2
Study type: Interventional

This pilot study is being done to see if the study medication, Rituximab, preserves kidney function after 12 months of taking the drug.